Bad News Teva Really Doesn't Need: A Potential Delay For Fremanezumab
Executive Summary
One of Teva's few bright spots is its leading position in the big new commercial opportunity for migraine, but its CGRP drug fremanezumab could now be delayed by an issue at third-party manufacturer Celltrion.
You may also be interested in...
Can Lilly’s Cluster Headache Data Differentiate Its CGRP Inhibitor?
Galcanezumab was able to reduce episodic cluster headaches compared to placebo, but missed statistical significance for chronic cluster headaches. Amgen’s Aimovig still is first in line to reach the market in the anti-CGRP class.
Teva Pushes CGRP Timeline Back To End Of 2018
Management said the migraine drug fremanezumab could launch in the US by the end of the year following discussions with the US FDA. The June timeline has been delayed by a Celltrion manufacturing issue.
Teva Pushes CGRP Timeline Back To End Of 2018
Management said the migraine drug fremanezumab could launch in the US by the end of the year following discussions with the US FDA. The June timeline has been delayed by a Celltrion manufacturing issue.